Comparative Pharmacology
Head-to-head clinical analysis: LIOTHYRONINE SODIUM versus THYROLAR 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIOTHYRONINE SODIUM versus THYROLAR 2.
LIOTHYRONINE SODIUM vs THYROLAR-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liothyronine is a synthetic form of triiodothyronine (T3), the active thyroid hormone. It binds to thyroid hormone receptors in the nucleus, modulating gene transcription and increasing basal metabolic rate, oxygen consumption, and thermogenesis. It enhances carbohydrate and lipid metabolism, and promotes normal growth and development.
Thyrolar-2 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the nucleus, modulating gene transcription and increasing metabolic rate, oxygen consumption, and protein synthesis.
25-75 mcg orally once daily; initial dose 25 mcg daily, titrate by 12.5-25 mcg increments every 1-2 weeks based on response.
1/2 to 1 tablet (30-60 mg liotrix) orally once daily, titrated every 2-4 weeks by 1/2 tablet increments based on clinical response and thyroid function tests.
None Documented
None Documented
Approximately 1-2 days in euthyroid patients; shorter in hyperthyroidism, prolonged in hypothyroidism. Clinical context: requires monitoring of thyroid function tests for dose adjustment.
6-7 days (euthyroid); clinical context: steady-state reached in 4-6 weeks
Primarily renal (approximately 50% as unchanged drug and metabolites); minor biliary/fecal elimination.
Renal: 40% (as glucuronide and sulfate conjugates); Fecal: 20% (unabsorbed); Biliary: minor (<5%)
Category A/B
Category C
Thyroid Hormone
Thyroid Hormone